Brand Name
Mircera
Generic Name
Glycol-Epoetin
View Brand Information FDA approval date: October 24, 2014
Classification: Erythropoiesis-stimulating Agent
Form: Injection
What is Mircera (Glycol-Epoetin)?
Mircera is an erythropoiesis-stimulating agent indicated for the treatment of anemia associated with chronic kidney disease in: adult patients on dialysis and adult patients not on dialysis.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Randomized, Open-label, Comparative Clinical Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Summary: BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.